1. Medtech Insight

Artificial Intelligence: US FDA Plans Guidances On Algorithm Bias, Product Development

 
• By Derrick Gingery

Cross-center AI strategy features collaboration between drug, biologic, device and combination product staff to ensure regulatory predictability. ‘Assurance labs’ offering independent valuation of models should be available by year-end as part of FDA’s involvement with Coalition for Health AI.

artificial intelligence
THE FDA ALSO IS PART OF THE COALITION FOR HEALTH AI, WHICH IS WORKING TO ADVANCE THE TECHNOLOGY IN HEALTH CARE. • Source: Shutterstock

Identifying and fighting bias in artificial intelligence will be one of many priorities for the US Food and Drug Administration going forward as it enhances its regulatory capacity for the technology.

The FDA’s drug, biologic, and device centers, as well as its Office of Combination Products, will collaborate to ensure regulatory certainty and allow for innovation with AI. In a 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

More from Digital Technologies